Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Updated Oct 20, 2026

Cooperative agreement from the National Institutes of Health, open to small businesses. Closes Nov 19, 2026, 30 days left.

Opportunity number	PAR-25-226
Agency	National Institutes of Health
Funding type	Cooperative agreement
Field	Health
Cost sharing or matching	Not required
Assistance listing	93.242
Posted	Nov 22, 2024
Closes	Nov 19, 2026 (30 days left)
Add the deadline to	Google Calendar

Who can apply

State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and state controlled institutions of higher education
Native American tribal governments (federally recognized)
Public housing authorities and Indian housing authorities
Native American tribal organizations (other than federally recognized tribal governments)
Nonprofits with 501(c)(3) status, other than institutions of higher education
Nonprofits without 501(c)(3) status, other than institutions of higher education
Private institutions of higher education
For-profit organizations other than small businesses
Small businesses
Others (see the eligibility notes)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Description

The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease.

This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.

Full announcement and how to apply on Grants.gov

Health grants right now

There are 350 open federal grants in health that small businesses may apply for; 33 close within 30 days. The median award ceiling is $500,000. The agencies offering the most are National Institutes of Health, Centers for Disease Control and Prevention - ERA and Centers for Disease Control - NCBDDD. Grants in this field stay open a median of 1031 days; this one is open for 727 days.

Who has won this program before

University Of North Carolina AT Chapel Hill $977.0 million · from Jun 29, 2006
The Johns Hopkins University $282.0 million · from Jun 29, 2006
Rutgers, The State University $179.7 million · from Jul 1, 2003
Salk Institute For Biological Studies, SAN Diego, California, The $92.4 million · from Sep 1, 2022
Allen Institute $91.9 million · from Aug 22, 2022

The largest grants and cooperative agreements under assistance listing 93.242 with payments since Oct 1, 2025, from USAspending.gov. Amounts are each award's total.